Drug Profile
Research programme: human monoclonal antibodies - Athersys/Medarex
Alternative Names: Human monoclonal antibodies research programme - Athersys/MedarexLatest Information Update: 20 Mar 2007
Price :
$50
*
At a glance
- Originator Athersys; Medarex
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 20 Mar 2007 No development reported - Preclinical for Cancer in USA (unspecified route)
- 02 Jul 2002 This programme is still in active development
- 24 Aug 2000 Preclinical development for Cancer in USA (Unknown route)